

TABLE 86: PATIENT CHARACTERISTICS — STUDIES OF TREATMENT-EXPERIENCED PATIENTS FROM TR0007

AUTHOR, YEAR, STUDY NAME	TREATMENT GROUP	ITT, N	AGE, MEAN (SD) OR MEDIAN (RANGE)	% MALE	TREATMENT HISTORY WITH PR (%)			HCV GENO-TYPE SUBTYPE (%)		METAVIR FIBROSIS SCORE (%)					VIRAL LOAD, MEAN LOG ₁₀ (SD)/ MEDIAN (RANGE)
					RELAPSE	PARTIAL	NULL	1a	1b	F0	F1	F2	F3	F4	
Studies included in the NMA															
Bacon et al. 2011, RESPOND2	PR48 2b	80	52.9 (8.0)	72	64	36	0	58	42	6	54	16	6	13	6.5 (0.7)
	B32 PR36/48 2b RGT	162	52.9 (7.4)	60	65	35	0	58	41	5	49	19	9	10	6.6 (0.5)
	B44 PR48 2b	161	52.3 (7.7)	70	64	36	0	60	38	3	48	22	6	14	6.7 (0.6)
Forns et al. 2014, PROMISE	PR48 2a	133	50.3 (10.76)	59	100	0	0	41	59	36 ^a		39	11	14	6.5 (0.6)
	SIM12 PR24/48 2a RGT	260	49.7 (10.27)	69	100	0	0	42	57	35 ^a		32	18	16	6.4 (0.6)
Zeuzem et al. 2011, REALIZE	PR48 2a	132	49.9 (9.74)	67	52	20	28	45	45	27 ^a		29	22	23	6.6 (SE 0.05)
	T12 PR48 2a q8	266	50.7 (8.51)	69	55	18	27	44	45	19 ^a		31	23	27	6.6 (SE 0.03)
	T12 PR48 2a LI q8 ^b	264	51 (8.24)	72	53	18	28	46	44	26 ^a		27	22	25	6.6 (SE 0.04)
Zeuzem et al. 2014, ASPIRE	PR48 2a	66	50.5 (22 to 66)	64	41	35	24	41	59	11	28	25	20	16	6.6 (5.2 to 7.6)
	SIM12 PR48 2a	66	48 (20 to 63)	68	39	35	26	46	55	8	29	27	17	20	6.6 (3.5 to 7.5)

B = boceprevir; F0 = no fibrosis; F1 = portal fibrosis without septa; F2 = portal fibrosis with rare septa; F3 = numerous septa without cirrhosis; F4 = cirrhosis; HCV = hepatitis C virus; ITT = intention-to-treat; NMA = network meta-analysis; PR = pegylated interferon 2a or 2b plus ribavirin; q8 = every 8 hours; RGT = response-guided therapy; SD = standard deviation; SE = standard error; T = telaprevir.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.

^a Proportion of patients with METAVIR F0 or F1.

^b Not a Health Canada-recommended dosage regimen.